COMPASS Pathways Plc Sponsored ADR CMPS 深 沪
已收盘 02-06 16:00:00 美东时间
6.19
+0.480
+8.41%
华盛通- 最 高6.2479
- 今 开5.90
- 成交量 112.93万股
- 最 低 5.72
- 昨 收 5.71
- 总市值 5.94亿
- 52周最高 8.20
- 市盈率 静 --
- 换手率 1.18%
- 52周最低 2.25
- 委 比 97.57%
- 总股本 9601.70万
- 历史最高 61.69
- 量 比 0.75
- 振 幅 9.25%
- 历史最低 2.25
- 每 手 1
- 风险率 1.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BUZZ-U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm
BUZZ-U.S. STOCKS ON THE MOVEx-IDEX Corp, Union Pacific, Qualcomm Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500, Nasdaq and the Dow fell, as the market still grappled wi
02-05 02:42
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
RBC Capital Maintains Outperform on Compass Pathways, Raises Price Target to $21
RBC Capital analyst Leonid Timashev maintains Compass Pathways (NASDAQ:CMPS) with a Outperform and raises the price target from $16 to $21.
01-23 23:14
Compass Pathways Teams Up With Radial Health to Expand Access to Psychedelic Mental Health Treatment
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial
01-06 19:32
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $11
Morgan Stanley analyst Vikram Purohit maintains Compass Pathways (NASDAQ:CMPS) with a Overweight and raises the price target from $10 to $11.
2025-11-06 02:04
CORRECTION: Compass Pathways Q3 Adj. EPS $(0.38) Beats $(0.39) Estimate
Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.39) by 2.56 percent. This is a 32.14 percent increase over losses of $(0.56) per share from
2025-11-04 22:38
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Evoke Pharma (NASDAQ:EVOK) shares moved upwards by 134.4% to $10.76 dur...
2025-11-04 20:06
NeuroKaire Enters R&D Collaboration With COMPASS Pathways To Advance Precision Psychiatry And Neurology
Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health NeuroKaire, a pioneer in precision psychiatry and neurology,
2025-10-30 20:38
Compass Pathways Appoints Dr. Jeffrey Jonas to Board
COMPASS Pathways ( ($CMPS) ) has shared an update. On October 26, 2025, Compass...
2025-10-29 18:57
